Organogenesis ORGO
1.41
(0.01)
(0.70%)
as of 25 Sep
- Market cap
- $207.1M
- P/E
- 0.0×
Follow ORGO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (53.31%) | (5.97%) | 7.11% | (5.02%) |
+8 more TTM periods Free account |
|
| (23.44%) | (2.95%) | 3.65% | (2.80%) | ||
ROIC |
(19.97%) | 0.97% | 12.78% | (2.71%) | |
Return on Tangible Assets |
(41.53%) | (4.90%) | 5.47% | (4.66%) | |
Average Days of Receivables |
80.54 | 82.90 | 140.68 | 132.42 | |
Free Cash Flow per Share |
0.16 | 0.13 | (0.19) | (0.41) | |
Free Cash Flow |
20.84 | 17.08 | (24.46) | (51.65) | |
Capital Expenditures |
(11.13) | (13.67) | (14.15) | (12.86) | |
Piotroski F-Score |
3.00 | 4.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
15.53% | 8.81% | (2.53%) | (12.06%) | |
Accounts Receivable Turnover |
4.13 | 4.67 | 3.45 | 3.45 | |
Accounts Payable Turnover |
4.60 | 5.24 | 4.52 | 3.70 | |
Inventory Turnover |
4.35 | 4.83 | 4.93 | 3.56 | |
Average Days of Payables |
78.84 | 74.83 | 84.80 | 123.72 | |
Days of Inventory on Hand |
78.81 | 74.34 | 78.63 | 121.76 | |
Tax Rate |
1.42 | (0.36) | (0.21) | (1.16) | |
Research and Development Expense of Revenue |
12.45% | 9.53% | 7.90% | 9.84% | |
Selling, General and Administrative Expense of Revenue |
65.38% | 61.96% | 57.83% | 64.47% | |
Share Based Compensation of Revenue |
3.08% | 2.64% | 2.36% | 2.55% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.31) | (2.11) | (0.51) | 2.90 | |
Depreciation/Fixed assets |
0.32 | 0.32 | 0.26 | 0.34 | |
Capex/Depreciation |
(0.34) | (0.41) | (0.53) | (0.49) | |
Revenue per Share |
3.56 | 4.03 | 4.45 | 3.67 | |
Operating CF per Share |
0.25 | 0.24 | (0.08) | (0.31) | |
Capex per Share |
(0.09) | (0.11) | (0.11) | (0.10) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
(22.23%) | (2.83%) | 3.55% | (2.88%) |
Columns are period end dates